Delivery of agents to inflamed tissues using folate-targeted liposomes
AssigneePurdue Research Foundation
InventorsPhilip Stewart LOW, Scott POH
Life of this patent
Estimating the term…
Abstract
The invention described herein pertains to folate-receptor targeted agents comprising therapeutic agents useful for the treatment of inflammatory disease, including folate-receptor targeted liposomes (folate-targeted liposomes) containing entrapped therapeutic agents and folate-receptor targeted dendrimers conjugated to therapeutic agents (folate-targeted dendrimer conjugates), useful for the treatment of inflammatory disease, including auto-immune disease, as well as to folate-targeted liposomes containing entrapped imaging agents and dendrimer conjugates conjugated to imaging agents, for use in the diagnosis and monitoring of treatment in such disease.
Claims9
-11. (canceled)
A method treating an inflammatory disease in a subject in need thereof, the method comprising administering a folate-receptor targeted liposomal composition comprising a lipid bilayer and an anti-inflammatory agent entrapped in the lipid bilayer.
(canceled)
A composition comprising a folate-targeted liposomal composition comprising an imaging or visualizing agent as an entrapped agent and further comprising at least one pharmaceutically acceptable carrier or excipient, wherein the lipid bilayer of the liposomal composition is primarily composed of DSPC/cholesterol with a mol ratio of about 56:40 and, wherein the hydrophilic polymer of the folate targeting conjugate is a PEG having an average molecular weight of about 200-5000 in which the end groups, prior to attachment, are independently amino, hydroxy, thiol or carboxy;
- and wherein the folate targeting conjugate is present at about 0.01 mol % to about 1 mol % in the lipid bilayer.
17-30. (canceled)
Dependencies are inferred from the claim text.